Table 1. MPN Patient characteristics.

Patient	Diagnosis	Gender	Age at diagnosis	JAK2V617F mutation	Response to Vorinostat	Response to Ruxolitinib
1	AML (Post-PV)	F	64	positive	++	++
2	PV	F	60	positive	++	n.d.
3	AML	F	55	negative	+++	++
4	ET	M	38	negative	+	+
5	MPN-U	M	45	negative	+	-
6	ET	F	72	negative	+++	+
7	AML (Post-PV)	M	76	positive	++	+
8	MPN-CEL/HES	F	23	negative	++	+
9	PV	F	52	negative	++	-

AML–Acute Myeloid Leukaemia; PV–Polycythaemia Vera; ET–Essential Thrombocytosis; MPN-U—Myeloproliferative Neoplasm–Unclassified; MPN-CEL/HES—Myeloproliferative Neoplasm with chronic eosinophilic leukemia/hypereosinophilic syndrome; F–Female; M–Male; n.d.–not determined; Response to Vorinostat and to Ruxolitinib–these represent the Viability Index (VI) of Lin^-CD34⁺ patients cells treated with Vorinostat and Ruxolitinib without stroma (- →1.00>VI>0.91; + → 0.90>VI>0.51; ++ → 0.50>VI>0.21 and +++ → 0.20>VI>0.00).